1-5 of 5
Maria Corinna Palanca-Wessels, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Youn H. Kim, MD, H. Miles Prince, MD FRACP, FRCPA, Sean Whittaker, MB, ChB, FRCP, MD, Steven M. Horwitz, MD, Madeleine Duvic, MD, Oliver Bechter, Jose A. Sanches, Rudolf Stadler, MD, Julia Scarisbrick, MD FRCP, MBBS, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Lauren C. Pinter-Brown, MD, Pablo L. Ortiz-Romero, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, Michael Weichenthal, MD, Jan Walewski, MD, David C. Fisher, MD PhD, Marise McNeeley, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Julie Lisano, Martha Li, Hui-Min Lin, PhD, Meredith Little, MPH, William L. Trepicchio, PhD, Reinhard Dummer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2018-99-112847
Published: 2018
Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Steven M. Horwitz, MD, Julia J. Scarisbrick, MD FRCP, MBBS †, Reinhard Dummer, MD, Madeleine Duvic, MD, Youn H. Kim, MD, Jan Walewski, MD, Sean Whittaker, MB, ChB, FRCP, MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Jose A. Sanches, PhD, Pablo L. Ortiz-Romero, MD PhD, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, FRACP,FRCPA,MBBS, Stephane Dalle, MD PhD, Michael Weichenthal, MD, David C. Fisher, MD, Rudolf Stadler, MD, Tatyana A Feldman, MD, Timothy M. Kuzel, MD, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Hui-Min Lin, PhD, Yi Liu, PhD, Meredith Little, MPH, H. Miles Prince, MD FRACP, FRCPA
Journal: Blood
Blood (2017) 130 (Supplement 1): 1509.
https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509
Published: 2017
Journal Articles

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Youn H Kim, MD, Sean Whittaker, MB, ChB, FRCP, MD, Steven M Horwitz, MD, Madeleine Duvic, MD, Reinhard Dummer, MD, Julia J Scarisbrick, MBChB FRCP MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD PhD, Pascal Wolter, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Erin Zagadailov, PharmD, MS, William L Trepicchio, PhD, Yi Liu, PhD, Meredith Little, MPH, H Miles Prince, MD
Journal: Blood
Blood (2016) 128 (22): 182.
https://doi.org/10.1182/blood.V128.22.182.182
Published: 2016
Journal Articles

Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study

Nancy L. Bartlett, MD, Mitchell R. Smith, MD, Ranjana Advani, MD, Tatyana Feldman, MD, Kerry J. Savage, MDMSc, Maria Corinna Palanca-Wessels, MD PhD, Tanya Siddiqi, MD
Journal: Blood
Blood (2014) 124 (21): 629.
https://doi.org/10.1182/blood.V124.21.629.629
Published: 2014
Journal Articles

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD PhD, Christopher A. Yasenchak, MD
Journal: Blood
Blood (2014) 124 (21): 294.
https://doi.org/10.1182/blood.V124.21.294.294
Published: 2014